ERK1-mediated immunomodulation of mesenchymal stem cells ameliorates inflammatory disorders.

ABSTRACT: Immune system disorders, especially T cell disorders, are important therapeutic targets of mesenchymal stem cells (MSCs) in many autoimmune diseases (ADs). Although extracellular regulated protein kinases (ERKs) play a role in MSC therapy by promoting T cell apoptosis, the mechanism remains unclear. Our findings indicate that ERK1^-/- bone marrow MSCs (BMMSCs), but not ERK2^-/- BMMSCs, failed to promote T cell apoptosis due to incapacity to activate the ETS2/AURKA/NF-κB/Fas/MCP-1 cascade. Moreover, ERK1^-/- BMMSCs were unable to upregulate regulatory T cells and suppress T helper 17 cells. Licochalcone A (LA), which promotes ERK pathway activation, enhanced the therapeutic efficacy of MSC therapy in ulcerative colitis

SUBMITTER: Zhang Q 

PROVIDER: S-EPMC10543658 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature